GALT - Galectin Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.93
+0.88 (+14.55%)
At close: 4:00PM EDT

6.94 +0.01 (0.14%)
After hours: 4:02PM EDT

Stock chart is not supported by your current browser
Previous Close6.05
Open6.50
Bid6.50 x 1400
Ask7.00 x 800
Day's Range6.14 - 6.98
52 Week Range1.28 - 9.49
Volume2,257,428
Avg. Volume743,643
Market Cap283.533M
Beta3.96
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateMar 26, 2018 - Mar 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • MarketWatch8 hours ago

    Galectin stock lifts 15% premarket on early cancer combination trial results

    Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .

  • GlobeNewswire8 hours ago

    Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial

    Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). NORCROSS, Ga., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced additional preliminary clinical data from cohort 3 of an investigator-initiated Phase 1b clinical trial of GR-MD-02 used in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic melanoma for which KEYTRUDA is indicated or those patients whose melanoma progressed during or recently after KEYTRUDA monotherapy.

  • Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?
    Zacks2 days ago

    Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?

    Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

  • Investopedia20 days ago

    Penny Stocks to Buy Using Technical Analysis for September 2018

    Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.

  • ACCESSWIRElast month

    3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum

    CORAL GABLES, FL / ACCESSWIRE / August 21, 2018 / Once again the biotechnology sector is heading higher. The SPDR S&P Biotech ETF (XBI), iShares NASDAQ Biotechnology Index ETF (IBB) and Health Care SPDR ETF (XLV) are all green today. A number of these biotechnology companies both large and small have been capitalizing on the move that the sector has been making.

  • Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock?

    Investors in Galectin Therapeutics (GALT) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswirelast month

    Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update

    Richard Uihlein, Chairman of the Board, added, “Galectin’s new leadership is focused on planning and conducting additional supportive work to prepare for a Phase 3 trial for GR-MD-02 in NASH cirrhosis based on the positive effects of GR-MD-02 on HVPG.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Conn's, Herman Miller, TrueBlue, Brandywine Realty Trust, Tenneco, and Galectin Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Aug. 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conn's, ...

  • 3 Stocks That Could Double Your Money
    Motley Fool2 months ago

    3 Stocks That Could Double Your Money

    Find out why these three biotech stocks could be huge winners.

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others.Under monitoring this morning are four equities: Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).

  • Investopedia3 months ago

    Penny Stocks to Buy Using Technical Analysis

    July's technical analysis penny stock action list includes breakout, pullback and momentum plays, along with proposed stop losses.

  • Why Galectin Therapeutics Stock Bolted Higher Today
    Motley Fool3 months ago

    Why Galectin Therapeutics Stock Bolted Higher Today

    Galectin's new patent for its lead drug candidate sent its shares higher today.

  • GlobeNewswire3 months ago

    Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis

    Galectin Therapeutics, Inc. (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631  titled "Method and Treatment of Pulmonary Fibrosis.” The patent's principal claims cover method of use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent is expected to provide broad protection for the use of GR-MD-02 for compositions, methods of using and methods of manufacturing compositions capable of treating pulmonary fibrosis. The patent coverage extends to 2032.

  • Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?
    Zacks3 months ago

    Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?

    Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

  • Business Wire3 months ago

    Company Profile for Galectin Therapeutics Inc.

    Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases.

  • 2 Clinical-Stage Biotech Stocks That Could Soar Next Week
    Motley Fool3 months ago

    2 Clinical-Stage Biotech Stocks That Could Soar Next Week

    Shares of Galectin Therapeutics and Verastem should both head higher in the coming week. Here's why.

  • Market Sentiment Around Loss-Making Galectin Therapeutics Inc (NASDAQ:GALT)
    Simply Wall St.3 months ago

    Market Sentiment Around Loss-Making Galectin Therapeutics Inc (NASDAQ:GALT)

    Galectin Therapeutics Inc’s (NASDAQ:GALT): Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The US$330.23M market-capRead More...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool3 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can the momentum continue for these red-hot biotech stocks?

  • 3 NASH Stocks That Could Soar in the Second Half of 2018
    Motley Fool3 months ago

    3 NASH Stocks That Could Soar in the Second Half of 2018

    The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.

  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zacks3 months ago

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Flex Pharma and Galectin Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 14, 2018 / Flex Pharma was one of the biggest decliners in the stock market yesterday after the company announced it would be stopping two ongoing trials due to safety concerns and that it would be eliminating 60% of its workforce. Shares of Galectin saw gains after announcing that it has chosen the company’s COO to be the new chief executive. Flex Pharma, Inc. shares took a heavy tumble in Wednesday trading, closing the day down about 75%.

  • ACCESSWIRE4 months ago

    Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin Therapeutics

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Tandem shares saw an increase in their share price after an analyst at Piper Jaffray upped his price target to $13 from $8. Shares of Galectin Therapeutics also saw a rise after the company announced its plans to begin a Phase 3 clinical trial program of GR-MD-02, its galectin-3 inhibitor in Nash cirrhosis. Tandem Diabetes Care, Inc. shares closed up 25.22% yesterday but lost some of those gains in after-hours trading.